Latest / Raleigh News Today | 2 Min News | The Daily News Now!
Lilly Stock Soars to $1400 | Raleigh News
JPMorgan analyst Chris Schott just raised his price target for Eli Lilly to $1,400, maintaining an “Overweight” rating as the stock hits a new yearly high. Driven by explosive global sales of Mounjaro and Zepbound — together generating $12.8 billion in Q1 — revenue surged 55% to nearly $20 billion. Eli Lilly has boosted its full-year revenue forecast to $82–85 billion. A new Medicare program starting July 1 will cover Zepbound and Foundayo at just $50/month, potentially reaching 20 million eligible patients. Schott also highlights a deep, defensible moat with a strong pipeline including…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.